gms | German Medical Science

57. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie (DGNN)

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie

12. - 15.09.2012, Erlangen

Banner: 57. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie

Expression patterns of EGFR-, PDGFR- and VEGFR –IHC in recurrent WHO grade III meningiomas

Meeting Abstract

  • presenting/speaker Kathrin Geiger - Uniklinikum Dresden, Dept. Neuropathology, Institute for Pathology, Dresen, Germany
  • Tareq Juratli - Uniklinikum Dresden, Dept. Neurosurgery, Dresden, Germany
  • Charlotte Mierke - Uniklinikum Dresden, Dept. Neurosurgery, Dresden, Germany
  • Matthias Kirsch - Uniklinikum Dresden, Dept. Neurosurgery, Dresden, Germany
  • Matthias Meinhardt - Uniklinikum Dresden, Dept. Neuropathology, Institute for Pathology, Dresen, Germany
  • Gabriele Schackert - Uniklinikum Dresden, Dept. Neurosurgery, Dresden, Germany

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie. 57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN). Erlangen, 12.-15.09.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12dgnnPP3.31

DOI: 10.3205/12dgnn075, URN: urn:nbn:de:0183-12dgnn0754

Veröffentlicht: 11. September 2012

© 2012 Geiger et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

The purpose of this study was to investigate the expression level of the epidermal growth factor receptor (EGFR),the platelet derived growth factor receptor 1-alpha (PDGFR) and the vascular endothelial growth factor receptor (VEGFR) by immunohistochemistry (IHC) in recurrent human meningiomas.

We tested 12 cases of recurrent menigiomas with secondary malignization in comparison with 10 recurrent meningiomas without malignization and 8 normal control tissues from autopsy brains, containing regular leptomeninx for expression of EMA, MIB-1, EGFR, PDGFR and VEGFR by immunochemistry (IR) using the indirect peroxidase technique on tissue microarrays (TMA) of paraffin-embedded specimens. TMA samples were chosen on the basis of viewed full size slides and contained 1–5 samples per tumor with a diameter of 1.5 mm each. Staining was evaluated using a semiquantitative scoring system except for MIB-1 where percentages were calculated. Chi-square test was used for statistical evaluation.

We found EMA -IHC of varying levels in all meningiomas and in regular leptomeninges. Grade I meningiomas showed proliferation rates below 6% regardless of recurrence. High proliferation rates were associated with malignancy (up to 40% of tumor cells). Recurrent meningiomas with secondary malignization showed increasing proliferation with each recurrence. Overexpression of EGFR was associated with malignancy (p < 0.01) and increased with recurrence (median score 2.3) While PDGFR and VEGFR scores were higher in malignant tumors, the difference was not significant.

Our data demonstrate the overexpression of EGFR in association with malignancy of meningiomas. Thus, EGFR may provide a therapeutic target for the treatment of inoperable malignant meningioma.